

# Study of CM313(SC) Injection in Subjects With Platelet Transfusion Refractoriness

NCT06792019

---

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Keymed Biosciences Co.Ltd
Enrollment	110 participants

## Key Eligibility Criteria

---

### Inclusion (5)

- Thrombocytopenia dependent on platelet transfusions and diagnosed with platelet transfusion refractoriness.
- Presence of one or more kinds of antiplatelet antibodies.
- Male or female, age ≥ 18 years.
- The Eastern Cooperative Oncology Group (ECOG) physical status score ≤ 2.
- Willing and able to comply with the requirements for this study and written informed consent.

### Exclusion (6)

- Diagnosed with Idiopathic thrombocytopenic purpura.
- Platelet transfusion refractoriness caused by non-immune factors.
- Previously treated with the anti-CD38 monoclonal antibody.
- Have an allergy to humanized monoclonal antibody or any part of CM313.
- Pregnant or breastfeeding females, or females planning to become pregnant during the study.
- ... and 1 more (see full listing online)

## Locations (1 total)

---

Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin Municipality, China